MRNA240726P102000
- 0.05
- -0.10-66.67%
Moderna Newsroom
Check Out What Whales Are Doing With MRNA
Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ:MRNA).And retail traders should know.We noticed this today when the trades showed up on publicly available
Moderna Insider Sold Shares Worth $1,842,651, According to a Recent SEC Filing
Noubar Afeyan, Director, on July 17, 2024, sold 15,000 shares in Moderna (MRNA) for $1,842,651. Following the Form 4 filing with the SEC, Afeyan has control over a total of 6,886,164 shares of the
Here Are Big Pharma's Leading Blockbuster Makers
Moderna (NASDAQ:MRNA) Shareholders Have Earned a 54% CAGR Over the Last Five Years
Decoding Moderna's Options Activity: What's the Big Picture?
Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.Looking at options history for Moderna (NASDAQ:MRNA) we detected 8 trades.If we consider the specifics of each
Jefferies Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $180
Jefferies analyst Michael Yee maintains $Moderna(MRNA.US)$ with a buy rating, and maintains the target price at $180.According to TipRanks data, the analyst has a success rate of 45.8% and a total
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
More than half of the states in the U.S. are experiencing significant Covid-19 activity in wastewater, and President Joe Biden remains in isolation after announcing Wednesday he caught the virus for
Moderna's Quarterly Earnings Preview: What You Need to Know
Moderna (MRNA) Stock Moves -0.93%: What You Should Know
Incyte, Moderna Among Most Shorted S&P 500 Healthcare Stocks in June
Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by more than 100 points on Friday. Investors, meanwhile, focused on some notable insider trades.When insiders sell shares, it could be a preplanned sale, or could
Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing
Noubar Afeyan, Director, on July 10, 2024, sold 15,000 shares in Moderna (MRNA) for $1,756,177. Following the Form 4 filing with the SEC, Afeyan has control over a total of 6,901,164 shares of the
Is Moderna Stock a Buy?
Moderna (NASDAQ: MRNA) went from being an unknown biotech to a household name thanks to its work developing and marketing one of the most successful COVID-19 vaccines.
Moderna, Inc. (NASDAQ:MRNA) Is Favoured by Institutional Owners Who Hold 68% of the Company
Form 144 | Moderna(MRNA.US) Director Proposes to Sell 1.74 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 10, $Moderna(MRNA.US)$ Director NOUBAR B AFEYAN intends to sell 15,000 shares of its common stock on Jul 10, with a total market value of approximately $1.74 million.
Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures
In a recent development, Flagship Pioneering, the venture capital firm known for backing Moderna (NASDAQ:MRNA) has successfully secured a whopping $3.6 billion in funding.What Happened: Flagship
Redburn Raises Moderna's Price Target to $117 From $116
Moderna (MRNA) has an average outperform rating and a price target range of $62 to $310, according to analysts polled by Capital IQ.Price: 116.68, Change: +0.61, Percent Change: +0.53
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
Unusual Options Activity: TEVA, MAT and Others Attract Market Bets, TEVA V/OI Ratio Reaches 347.7
EST Jul 9th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options